<DOC>
	<DOCNO>NCT00236054</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy investigational anti-anxiety medication relative placebo patient generalize anxiety disorder ( GAD )</brief_summary>
	<brief_title>A 10-Week Efficacy Safety Study Gabitril Treatment Adults With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Tiagabine</mesh_term>
	<criteria>Subjects 18 64 year age ( inclusive ) eligible participate satisfy DSMIVTR criterion GAD , well meeting require screening baseline visit score series psychiatric evaluation ( i.e. , HAMA , HADS , MADRS CGIS ) . Have previously unresponsive two adequate course pharmacological treatment GAD Have diagnose psychiatric Axis I disorder ( except GAD ) principal diagnosis within past six month Have diagnose eat disorder within past six month Have history OCD , psychotic disorder , bipolar disorder antisocial personality disorder Have history alcohol substance abuse within past 3 month Have history seizure , include febrile seizure Have history head trauma associate loss consciousness within past 15 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>